Clinical data | |
---|---|
Other names | CP-26154, MLR-1023 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.230.742 |
Chemical and physical data | |
Formula | C11H10N2O2 |
Molar mass | 202.213 g·mol−1 |
3D model ( JSmol) | |
|
Tolimidone (CP-26154; MLR-1023) is a compound which was discovered by scientists at Pfizer, was found to stimulate secretion of gastric mucosa, and was in development by Pfizer as a drug candidate to treat gastric ulcers but was abandoned. [1] [2] [3] [4] After the patent on the compound expired, scientists at the company Melior Discovery identified it as a potential drug candidate for diabetes through a phenotypic screen. [4] The company proceeded to show that MLR-1023 is an allosteric activator of Lyn kinase with an EC50 of 63 nM. [5] [6] As of 2012 Melior was repurposing it for diabetes. [1] [7] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects [8] [9]
Compound 3 has been assigned the nonproprietary (USAN) name tolimidone
Clinical data | |
---|---|
Other names | CP-26154, MLR-1023 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.230.742 |
Chemical and physical data | |
Formula | C11H10N2O2 |
Molar mass | 202.213 g·mol−1 |
3D model ( JSmol) | |
|
Tolimidone (CP-26154; MLR-1023) is a compound which was discovered by scientists at Pfizer, was found to stimulate secretion of gastric mucosa, and was in development by Pfizer as a drug candidate to treat gastric ulcers but was abandoned. [1] [2] [3] [4] After the patent on the compound expired, scientists at the company Melior Discovery identified it as a potential drug candidate for diabetes through a phenotypic screen. [4] The company proceeded to show that MLR-1023 is an allosteric activator of Lyn kinase with an EC50 of 63 nM. [5] [6] As of 2012 Melior was repurposing it for diabetes. [1] [7] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects [8] [9]
Compound 3 has been assigned the nonproprietary (USAN) name tolimidone